News

The open-label, multicenter, dose-escalation Phase I trial is designed to evaluate an intravenous (IV) formulation of marizomib in combination with bevacizumab (Avastin) in these patients. Patient enrollment is

GC Group is an Israeli pharmaceutical R&D firm engaged in development of several new generic drug products of different types. As part of the deal, GC Group will

The drug was granted orphan drug status under the US Orphan drug Act following a review by the FDA of a package of pre-clinical data submitted by the

MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARd) agonist currently being evaluated by the company in high unmet need and orphan diseases. Recently, MBX-8025 also

The anti-cancer agent is designed to treat relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted

Betaseron is a prescription medicine used to reduce the number of relapses in people with relapsing forms of MS, which includes people who have had their first symptoms

In the US, Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are

ROS1-positive NSCLC occurs in approximately 1% of NSCLC cases and it represents a particular molecular subgroup of NSCLC. The breakthrough therapy designation was based on a data from

These products include 12 branded products, five authorized generic contracts and a product distributed by a third party in Australia pursuant to the terms of a distribution agreement.